Dronedarone: An Emerging Agent with Rhythm‐ and Rate‐Controlling Effects
- 3 August 2006
- journal article
- review article
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 17 (s2) , S17-S20
- https://doi.org/10.1111/j.1540-8167.2006.00583.x
Abstract
Of current antiarrhythmic agents, amiodarone is among the most effective with the additional advantage of having little proarrhythmic potential. However, it can cause potentially serious extracardiac side effects, stimulating the search for safer derivatives. Dronedarone, a new antiarrhythmic drug that is structurally related to amiodarone, lacks an iodine moiety and, thus, amiodarone's iodine‐related organ toxicity, while its methane sulfonyl group decreases lipophilicity so shortening half‐life and decreasing tissue accumulation. Electrophysiological studies show that dronedarone shares amiodarone's multichannel blocking effects, inhibiting transmembrane Na+, K+, Ca2+, and slow L‐type calcium channels, as well as its antiadrenergic effects. Unlike amiodarone, it has little effect at thyroid receptors. Possessing both rate‐ and rhythm‐control properties, dronedarone has proved safe and effective in preventing recurrence of atrial fibrillation (AF) in patients with persistent AF in the Dronedarone Atrial Fibrillation Study After Electrical Cardioversion (DAFNE) trial, the first prospective randomized trial to evaluate its efficacy and safety. Dronedarone has since undergone further extensive evaluation in three pivotal phase III trials. In two sister studies, the European Trial in Atrial Fibrillation or Flutter Patients Receiving Dronedarone for the Maintenance of Sinus Rhythm (EURIDIS) and American–Australian–African Trial with Dronedarone in Atrial Fibrillation/Flutter Patients for the Maintenance of Sinus Rhythm (ADONIS), dronedarone 400 mg b.i.d. showed significant efficacy against placebo in prevention of AF recurrence. Additionally, in patients with permanent AF, dronedarone was highly effective at controlling ventricular rate on top of standard rate‐controlling therapies in the Efficacy and Safety of Dronedarone for the Control of Ventricular Rate during Atrial Fibrillation (ERATO) study.Keywords
This publication has 27 references indexed in Scilit:
- Amiodarone versus Sotalol for Atrial FibrillationNew England Journal of Medicine, 2005
- Dronedarone: an amiodarone analogueExpert Opinion on Investigational Drugs, 2004
- Acute effects of dronedarone on both components of the cardiac delayed rectifier K+ current, HERG and KvLQT1/minK potassium channelsBritish Journal of Pharmacology, 2003
- Effects of Amiodarone and Dronedarone on Voltage‐Dependent Sodium Current in Human CardiomyocytesJournal of Cardiovascular Electrophysiology, 2003
- New Approaches to Atrial Fibrillation ManagementDrugs, 2002
- Guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American Society of Pacing and ElectrophysiologyEuropean Heart Journal, 2001
- Electrophysiological effects of dronedarone (SR 33589), a noniodinated amiodarone derivative in the canine heart: comparison with amiodaroneBritish Journal of Pharmacology, 2001
- Effects of dronedarone on Acetylcholine‐activated current in rabbit SAN cellsBritish Journal of Pharmacology, 2000
- SR 33589, a new amiodarone-like antiarrhythmic agent: anti-adrenoceptor activity in anaesthetized and conscious dogsEuropean Journal of Pharmacology, 1995